Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
April 29, 2025 | Market Access, US, access and pricing, agile, efficient, global, solution
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision.
Following Genesis Research Group’s recent expansion of its real-world data analytics capabilities and the appointment of Ki Park as VP, Market Access Strategy & Analytics, the innovative global HEOR, access & pricing and real-world evidence research organization has fully outlined its integrated market access offering.
Genesis Research Group leverages its proprietary RPR stakeholder engagement platform, a network of 3,500+ vetted payers, clinicians, and KOLs across 65 countries, coupled with deep expertise in access, pricing, HEOR, and real-world analytics, to deliver end-to-end solutions that drive commercial success.
Each of the following capabilities can be integrated to boost results or applied independently—helping clients to transform complex challenges throughout the product lifecycle into competitive advantages.
✅ Global strategic advisory
Navigate complex US and global challenges with clarity and confidence. The company’s experts partner with you to develop detailed strategies on product positioning, pricing, and value demonstration – maximizing commercial success through tailored, market-specific solutions.
✅ US data-driven analytics
Navigate the evolving US market landscape with advanced analytical solutions, from contracting strategy and product adoption to LOE analysis, co pay optimization, and IRA impact assessment. This end-to-end approach delivers robust, actionable insights that drive measurable results.
✅ RPR stakeholder insights
Empower strategic access and pricing decisions with RPR, a proprietary stakeholder engagement platform. Gain actionable and pressure-tested insights from 3,500+ vetted payers, clinicians, and KOLs across 65 countries – delivered faster and more robustly than traditional primary research methods.
✅ Analogue and landscape research
Establish strategic clarity through rigorous analogue lookbacks and detailed landscape assessments. Tailored secondary research servoces deliver precise benchmarking on pricing, reimbursement decisions, and HTA outcomes – seamlessly integrated with access and pricing, HEOR, and evidence generation expertise to reduce uncertainty and inform effective decision-making.
✅ A&P Flexible Integrated Teams (FIT)
Benefit from adaptable contracting models tailored to your specific needs, or build an agile, extended partnership with an innovative Access & Pricing FIT (Flexible Integrated Team) engagement for long-term strategic collaboration.
Visit Genesisrg.com to find out more, or contact solutions@genesisrg.com to ask how they can help you overcome your challenges.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group
A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...
Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences
This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...